Study shows how MS patients treated with Rituximab react to COVID-19 vaccination
MS patients treated with Rituximab have better responses to the COVID-19 vaccine if they have higher B cell counts.
Stay updated with breaking news from B Cell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MS patients treated with Rituximab have better responses to the COVID-19 vaccine if they have higher B cell counts.
Researchers developed novel lipid nanoparticle (LNP)-based messenger ribonucleic acid vaccine formulations against three pathogenic coronaviruses.
It's not often that a failed clinical trial leads to a scientific breakthrough. When patients in the UK started showing adverse side effects during a cancer immunotherapy trial, researchers at La Jolla Institute for Immunology (LJI) Center for Cancer Immunotherapy and University of Liverpool went back through the data and worked with patient samples to see what went wrong.
A new paper describes a novel method, using a specific molecule to engage T cell receptors and the virus receptor, the angiotensin-converting enzyme 2, at the same time.
In a recent study published in the journal Nature, the researchers investigated the impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) booster vaccine on memory B cells.